About 3DHEALS Company Directory:
3DHEALS updates this collection of public and private companies, government and non-government institutions, and any relevant research organizations in healthcare 3D printing, bioprinting, AR/VR, 3D technologies, on a weekly basis. Access to this directory is free to 3DHEALS Premium and Enterprise members.
Fluidform’s patented FRESH™ technology (off CMU) has been shown to be able to produce real functional beating human ventricles and heart valves, recreate complex branching vasculature down to the capillary scale, tailor alignment of cells to create muscle fibers and tissue anisotropy, and promote tissue regeneration in large animal studies, and even scale up to full-size organs based. Currently it is focusing on two commercial goals:
1) Cardiotoxicity model for drug screening/discovery. The company is working on developing an in-vitro human heart model that detects complex arrhythmias early in the pre-clinical discovery process. The hypothesis is that existing in-vitro models for testing cardiotoxicity is inferior due to their lack of geometric complexity and size.
2) Trans-catheter Aortic Valve. The team is working on a trans-catheter valve with reduced propensity for calcification, which is a common complication for existing valves.